COSCIENS Biopharma
COSCIENS Biopharma Inc. · CSCI (NASDAQ) · Toronto, ON · Pharmaceuticals
Latest R&D (CAD)
$4.1M
Period ended 2025-12-31
Revenue (CAD)
—
Intensity —
R&D by fiscal period
2025
$4.1M
2024
$11.4M
2023
$2.8M
2022
$1.8M
2021
$8.2M
2020
$2.0M
2019
$2.4M
2018
$3.8M
| Period end | R&D (CAD) | Revenue (CAD) | Native R&D | Form | Source |
|---|---|---|---|---|---|
| 2025-12-31 | $4,123,510 | — | $2,950,000 USD | 20-F | SEC EDGAR |
| 2024-12-31 | $11,374,819 | — | $8,304,000 USD | 20-F | SEC EDGAR |
| 2023-12-31 | $2,753,388 | $9,633,000 | $2,040,000 USD | 20-F | SEC EDGAR |
| 2022-12-31 | $1,784,082 | $18,840,000 | $1,371,000 USD | 20-F | SEC EDGAR |
| 2021-12-31 | $8,240,509 | — | $6,574,000 USD | 20-F/A | SEC EDGAR |
| 2020-12-31 | $2,020,299 | — | $1,506,000 USD | 20-F/A | SEC EDGAR |
| 2019-12-31 | $2,437,515 | — | $1,837,000 USD | 20-F | SEC EDGAR |
| 2018-12-31 | $3,798,992 | — | $2,932,000 USD | 20-F | SEC EDGAR |